From Alphastreet - Earnings Decoded. Market Intelligence Delivered · AlphaStreet Newsdesk · · 40s
TL;DR: Larimar Therapeutics Q3 2026 Results
Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies.
Larimar Therapeutics Inc. posted a $31.1M net loss for Q3 2026, narrowing per-share loss to $0.29 from $0.61 in Q3 2025. Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies. Larimar Therapeutics Inc. posted a net loss of $31.1M for Q3 2026. The per-share loss narrowed to $0.29 from $0.61 in Q3 2025, a 52.5% improvement.
- Q3 2026 Financial Results
- Per-Share Loss Narrowed
- Analyst Support
Read the story version — the same reporting as a swipeable deck of 3 cards.






